Genetic risk factors for serious infections in inflammatory bowel diseases

References

• Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis. 2013;7:107–12.
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EV Jr. Safety profile of IBD therapeutics: infectious risks. Gastroenterol Clin North Am. 2009;38:691–709.
   PubMed Web of Science ®Google Scholar
• Epple HJ. Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease. Dig Dis. 2009;27:555–559.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–630.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051–1063.
   PubMed Web of Science ®Google Scholar
• Dave M, Purohit T, Razonable R, et al. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis. 2014;20:196–212.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis. 2013;7:107–112.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205–210.
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–936.
   PubMed Web of Science ®Google Scholar
• Gajendran M, Umapathy C, Loganathan P, et al. Analysis of hospital-based emergency department visits for inflammatory bowel disease in the USA. Dig Dis Sci. 2016;61:389–399.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Pillot C, Oussalah A, et al. Urinary tract infections in hospitalized inflammatory bowel disease patients: a 10-year experience. Inflamm Bowel Dis. 2012;18:697–702.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385–1397.
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306:2331–2339.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887–895.
   PubMed Web of Science ®Google Scholar
• van der Have M, Oldenburg B, Fidder HH, et al. Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn’s disease. Dig Dis Sci. 2014;59:554–563.
   PubMed Web of Science ®Google Scholar
• Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317.
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–2078.
   PubMed Web of Science ®Google Scholar
• Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (in press) 2012;491:119–124.
   PubMed Web of Science ®Google Scholar
• Agnese DM, Calvano JE, Hahm SJ, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis. 2002;186:1522–1525.
   PubMed Web of Science ®Google Scholar
• Bronkhorst MW, Boye ND, Lomax MA, et al. Single-nucleotide polymorphisms in the Toll-like receptor pathway increase susceptibility to infections in severely injured trauma patients. J Trauma Acute Care Surg. 2013;74:862–870.
   PubMed Web of Science ®Google Scholar
• Sutherland AM, Walley KR, Russell JA. Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med. 2005;33:638–644.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Cagan A, Cai T, et al. Common genetic variants influence circulating vitamin D levels in inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:2507–2514.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Huang H, Nguyen DD, et al. Differential effect of genetic burden on disease phenotypes in Crohn’s disease and ulcerative colitis: analysis of a North American cohort. Am J Gastroenterol. 2014;109:395–400.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Nguyen DD, Sauk J, et al. Genetic polymorphisms in metabolizing enzymes modifying the association between smoking and inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20:783–789.
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–1517.
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Oxford EC, Nguyen DD, et al. Genetic risk factors for Clostridium difficile infection in ulcerative colitis. Aliment Pharmacol Ther. 2013;38:522–530.
   PubMed Web of Science ®Google Scholar
• Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther. 2011;13:101.
   PubMed Web of Science ®Google Scholar
• Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–575.
   PubMed Web of Science ®Google Scholar
• Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47:979–986.
   PubMed Web of Science ®Google Scholar
• Koltsova EK, Ley K. The mysterious ways of the chemokine CXCL5. Immunity. 2010;33:7–9.
   PubMed Web of Science ®Google Scholar
• Cai S, Batra S, Lira SA, et al. CXCL1 regulates pulmonary host defense to Klebsiella infection via CXCL2, CXCL5, NF-kappaB, and MAPKs. J Immunol. 2010;185:6214–6225.
   PubMed Web of Science ®Google Scholar
• Lindell DM, Lane TE, Lukacs NW. CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8(+) T cell efficacy. Eur J Immunol. 2008;38:2168–2179.
   PubMed Web of Science ®Google Scholar
• Packiriswamy N, Steury M, McCabe IC, et al. Bacterial dose-dependent role of G protein-coupled receptor kinase 5 in Escherichia coli-induced pneumonia. Infect Immun. 2016;84:1633–1641.
   PubMed Web of Science ®Google Scholar
• Dotan I, Allez M, Nakazawa A, et al. Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-gamma. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1630–G1640.
   PubMed Web of Science ®Google Scholar
• Ito R, Shin-Ya M, Kishida T, et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol. 2006;146:330–338.
   PubMed Web of Science ®Google Scholar
• Sarra M, Monteleone I, Stolfi C, et al. Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis. 2010;16:1332–1339.
   PubMed Web of Science ®Google Scholar
• Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41–101.
   PubMed Web of Science ®Google Scholar
• Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163–189.
   PubMed Web of Science ®Google Scholar
• Chesler DA, Reiss CS. The role of IFN-gamma in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 2002;13:441–454.
   PubMed Web of Science ®Google Scholar
• Reljic R. IFN-gamma therapy of tuberculosis and related infections. J Interferon Cytokine Res. 2007;27:353–364.
   PubMed Web of Science ®Google Scholar
• Pociask DA, Scheller EV, Mandalapu S, et al. IL-22 is essential for lung epithelial repair following influenza infection. Am J Pathol. 2013;182:1286–1296.
   PubMed Web of Science ®Google Scholar
• Yan Z, Yang J, Hu R, et al. Acinetobacter baumannii infection and IL-17 mediated immunity. Mediators Inflamm. 2016;2016:9834020.
   PubMed Web of Science ®Google Scholar
• Noda S, Tanaka K, Sawamura S, et al. Role of nitric oxide synthase type 2 in acute infection with murine cytomegalovirus. J Immunol. 2001;166:3533–3541.
   PubMed Web of Science ®Google Scholar
• Zaragoza C, Ocampo CJ, Saura M, et al. Inducible nitric oxide synthase protection against coxsackievirus pancreatitis. J Immunol. 1999;163:5497–5504.
   PubMed Web of Science ®Google Scholar
• Dambacher J, Beigel F, Zitzmann K, et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut. 2009;58:1207–1217.
   PubMed Web of Science ®Google Scholar
• Gilley J, Coleman MP. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol. 2010;8:e1000300.
   PubMed Web of Science ®Google Scholar
• Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11:954–963.
   PubMedGoogle Scholar
• McLean-Tooke A, Aldridge C, Waugh S, et al. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence? Rheumatology (Oxford). 2009;48:867–871.
   PubMed Web of Science ®Google Scholar